Physician
A2z Diagnostics LLC
A2z Diagnostics LLC was paid $3.21M by Medicaid between Feb 2019 and Nov 2024, across 25 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 60% of everything it billed.
33Billing provider infoA2Z DIAGNOSTICS LLC
EATONTOWN, NJ 07724
EATONTOWN, NJ 07724
33aNPI1487135448assigned 08/27/2018
33bProvider typeMedical Microbiology Physician
28Total paid$3.21M
24GClaims81,726
24DCodes billed25
24AFirst – last monthFeb 2019 – Nov 2024
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 3,382 | $438K | |
| 2020 | 9,590 | $479K | |
| 2021 | 43,391 | $1.47M | |
| 2022 | 17,900 | $600K | |
| 2023 | 4,596 | $144K | |
| 2024incomplete | 2,867 | $83K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 60% | 31,749 | 26,166 | $1.93M |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | 14% | 24,196 | 19,550 | $460K |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 10% | 1,436 | 1,335 | $328K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 4.0% | 2,738 | 2,366 | $127K |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 2.1% | 1,544 | 1,435 | $67K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.7% | 9,900 | 7,370 | $55K |
| 88342 | 1.7% | 1,539 | 1,384 | $54K | |
| 87631 | 1.1% | 1,107 | 990 | $36K | |
| 87581 | <1% | 1,516 | 1,409 | $30K | |
| 87486 | <1% | 1,517 | 1,410 | $30K | |
| 88313 | <1% | 1,507 | 1,358 | $29K | |
| 87507 | <1% | 92 | 92 | $21K |
13 more codes
| 88312 | <1% | 1,208 | $14K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 271 | $10K |
| 86328 | <1% | 212 | $7K | |
| 0202U | Oncology (prostate), multianalyte, gene expression profiling | <1% | 67 | $6K |
| 87811 | Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) | <1% | 75 | $3K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 228 | $2K |
| 88341 | <1% | 30 | $891.84 | |
| 0753T | <1% | 197 | $798.48 | |
| 0757T | <1% | 193 | $378.78 | |
| 0760T | <1% | 219 | $317.00 | |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | <1% | 25 | $191.44 |
| 0756T | <1% | 138 | $126.89 | |
| 99080 | 0% | 22 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAQUINO, MICHAEL (PRESIDENT)